Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi SNY announced that a phase III study evaluating its investigational oral BTK inhibitor, tolebrutinib, demonstrated clinically meaningful benefit in disability accumulation in patients with ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

(JAMA Neurology) The investigational Bruton's tyrosine kinase inhibitor tolebrutinib met its primary endpoint of delaying ...